Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796559 · ClinicalTrials.gov registry record · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
A NA study of Breast Cancer and Axillary Lymph Nodes, sponsored by Endomagnetics.
- Recruiting
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 2
- Study locations
NCT03796559: Recruiting NA study of Breast Cancer and Axillary Lymph Nodes, sponsored by Endomagnetics.
NCT03796559 is a NA study of Breast Cancer and Axillary Lymph Nodes that is actively recruiting participants, run by Endomagnetics. The registered enrollment target is 65 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796559, a NA study of Breast Cancer and Axillary Lymph Nodes, is actively recruiting participants, sponsored by Endomagnetics.
- RECRUITING
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.
Conditions Studied
Interventions
- DEVICE Magseed Marker
Study Locations (2)
Texas
- Baylor Medicine - Houston
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-06-13 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT03796559 shows while recruiting
NCT03796559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Magseed Marker is the first listed.
NCT03796559 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03796559 about?
NCT03796559 is a clinical study titled "Magseed Enabled Long-Term Localization of Axillary Lymph Nodes". The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.
What is the current status of trial NCT03796559?
This trial is currently recruiting. It is a NA study. The enrollment target is 65 participants. The study started on 2019-06-13. Estimated completion is 2026-05.
What conditions does trial NCT03796559 study?
This clinical trial studies the following conditions: Breast Cancer, Axillary Lymph Nodes.
What interventions are being tested in trial NCT03796559?
The interventions under investigation include: Magseed Marker (DEVICE).
Who is sponsoring clinical trial NCT03796559?
This trial is sponsored by Endomagnetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796559 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03796559's enrollment target sits among peer trials
65 722nd of 1224 higher than 501 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
- NCT04028063 · 65 participants · Phase 2
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI